Phase 2

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

March 8, 2021

https://clinicaltrials.gov/ct2/show/NCT04786262?type=Intr&cond=Diabetes+Mellitus%2C+Type+1&phase=0124&lupd_s=02%2F22%2F2021&lupd_d=14&sort=nwst

STUDY TITLE:
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

DESCRIPTION:
Conditions: Diabetes Mellitus, Type 1; Impaired Hypoglycemic Awareness; Severe Hypoglycemia
Intervention: Biological: VX-880
Sponsor: Vertex Pharmaceuticals Incorporated
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04786262

FIRST POSTED:
Mon, 08 Mar 2021 12:00:00 EST

LAST UPDATE POSTED:
03/08/21 06:09AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04786262?type=Intr&cond=Diabetes+Mellitus%2C+Type+1&phase=0124&lupd_s=02%2F22%2F2021&lupd_d=14&sort=nwst

Phase 2, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)

August 12, 2020

https://clinicaltrials.gov/ct2/show/NCT04509791?type=Intr&cond=Diabetes+Mellitus%2C+Type+1&phase=0124&lupd_s=07%2F29%2F2020&lupd_d=14&sort=nwst

STUDY TITLE:
MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)

DESCRIPTION:
Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Anti-Human Thymocyte Immunoglobulin, Rabbit
Sponsor: Universitaire Ziekenhuizen Leuven
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT04509791

FIRST POSTED:
Wed, 12 Aug 2020 12:00:00 EDT

LAST UPDATE POSTED:
08/12/20 07:22AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT04509791?type=Intr&cond=Diabetes+Mellitus%2C+Type+1&phase=0124&lupd_s=07%2F29%2F2020&lupd_d=14&sort=nwst

Islet Transplant in Patients With Type I Diabetes

July 30, 2020

https://clinicaltrials.gov/ct2/show/NCT03698396?type=Intr

https://clinicaltrials.gov/ct2/show/NCT03698396?type=Intr&cond=Diabetes+Mellitus%2C+Type+1&phase=0124&lupd_s=07%2F16%2F2020&lupd_d=14&sort=nwst

STUDY TITLE:
Islet Transplant in Patients With Type I Diabetes

DESCRIPTION:
Condition: Diabetes Mellitus, Type 1
Intervention: Biological: Allogenic Islet Cell Transplantation
Sponsor: Kenneth Brayman, MD
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03698396

FIRST POSTED:
Tue, 09 Oct 2018 12:00:00 EDT

LAST UPDATE POSTED:
07/30/20 07:16AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03698396?type=Intr&cond=Diabetes+Mellitus%2C+Type+1&phase=0124&lupd_s=07%2F16%2F2020&lupd_d=14&sort=nwst

Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy

November 28, 2019

https://clinicaltrials.gov/ct2/show/NCT02936843?type=Intr&cond=Diabetes+Mellitus%2C+Type+1&phase=0124&lupd_s=11%2F15%2F2019&lupd_d=14&sort=nwst

STUDY TITLE:
Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy

DESCRIPTION:
Conditions: Type 1 Diabetes; Peripheral Neuropathy
Interventions: Drug: Salsalate; Drug: PLACEBO
Sponsor: University of Michigan
Recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT02936843

FIRST POSTED:
Tue, 18 Oct 2016 12:00:00 EDT

LAST UPDATE POSTED:
11/29/19 07:17AM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT02936843?type=Intr&cond=Diabetes+Mellitus%2C+Type+1&phase=0124&lupd_s=11%2F15%2F2019&lupd_d=14&sort=nwst

Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2)

September 14, 2019

https://clinicaltrials.gov/ct2/show/NCT03941132?type=Intr&cond=type+1+diabetes&phase=01234&lup_d=14&lupd_s=02%2F10%2F2019&lupd_e=05%2F29%2F2019&sort=nwst

STUDY TITLE:
Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2)

DESCRIPTION:
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Ustekinumab; Drug: Placebo
Sponsors: University of British Columbia; Juvenile Diabetes Research Foundation; Janssen, LP
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03941132

FIRST POSTED:
Tue, 07 May 2019 12:00:00 EDT

LAST UPDATE POSTED:
May 7, 2019

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03941132?type=Intr&cond=type+1+diabetes&phase=01234&lup_d=14&lupd_s=02%2F10%2F2019&lupd_e=05%2F29%2F2019&sort=nwst

Effect of the SGLT-2 Inhibitor Dapagliflozin on IAH in Type 1 Diabetes

September 13, 2019

https://clinicaltrials.gov/ct2/show/NCT03556033

Study Type : Interventional
Estimated Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of the SGLT-2 Inhibitor Dapagliflozin on Impaired Awareness of Hypoglycemia in Type 1 Diabetes
Actual Study Start Date : November 23, 2018
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019